Mhairi Nimick

2024

Journal - Research Article

Garelja, M. L., Alexander, T. I., Bennie, A., Nimick, M., Petersen, J., Walker, C. S., & Hay, D. L. (2024). Pharmacological characterisation of erenumab, Aimovig, at two calcitonin gene-related peptide responsive receptors. British Journal of Pharmacology, 181, 142-161. doi: 10.1111/bph.16218

Conference Contribution - Published proceedings: Abstract

Hay, D., Nimick, M., Garelja, M., Alexander, T., Walker, C., & Banerjee, P. (2024). Pharmacological characterization of ubrogepant and atogepant in cAMP assays at human, rat and mouse calcitonin family receptors in transfected cells. Headache, 64(Suppl. 1), (pp. 11-12). doi: 10.1111/head.14716

Hay, D., Alexander, T., Nimick, M., Garelja, M., Walker, C., & Banerjee, P. (2024). Antagonism by ubrogepant and atogepant of agonist-mediated human CGRP receptor β-arrestin recruitment and internalization in transfected cells. Headache, 64(Suppl. 1), (pp. 3-4). doi: 10.1111/head.14716

2023

Journal - Research Article

Chand, R. R., Nimick, M., Cridge, B., & Rosengren, R. J. (2023). Investigating the contribution of major drug-metabolising enzymes to possum-specific fertility control. International Journal of Molecular Sciences, 24, 9424. doi: 10.3390/ ijms24119424

Finlay, D. B., Mackie, W., Webb, H. D. J., Thomsen, L. R., Nimick, M., Rosengren, R. J., … Glass, M., & Wiley, J. L. (2023). The piperazine analogue para-fluorophenylpiperazine alters timing of the physiological effects of the synthetic cannabinoid receptor agonist AMB-FUBINACA, without changing its discriminative stimulus, signalling effects, or metabolism. Pharmacology Biochemistry & Behavior, 23, 173530. doi: 10.1016/j.pbb.2023.173530

Conference Contribution - Published proceedings: Abstract

Burga, L., Pham, A., Nimick, M., Waqqar, S., Turner, P., Watanabe, E., & Bostina, M. (2023). Developing oncolytic Seneca Valey Virus for cancer treatment. Proceedings of the New Zealand Society for Biochemistry and Molecular Biology (NZSBMB) 50th Anniversary Conference. Retrieved from https://www.nzsbmb.org/conference

2022

Journal - Research Article

Palmer, H., Nimick, M., Mazumder, A., Taurin, S., Rana, Z., & Rosengren, R. J. (2022). Raloxifene suppresses tumor growth and metastasis in an orthotopic model of castration-resistant prostate cancer. Biomedicines, 10, 853. doi: 10.3390/biomedicines10040853

Conference Contribution - Poster Presentation (not in published proceedings)

Watanabe, E., Burga, L., Velamoor, S., Nimick, M., Easingwood, R., & Bostina, M. (2022, August). Effects of Seneca Valley virus with clinically available chemotherapeutic drugs on 3D tumour-like cell cultures of triple negative breast cancer cells. Poster session presented at the Advances in Microscopy Satellite Meeting: Queenstown Research Week, Queenstown, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Burga, L. N., Pham, A., Nimick, M., Turner, P., Watanabe, E., & Bostina, M. (2022, August). Developing oncolytic Seneca Valley Virus for cancer treatment. Verbal presentation at the Cancer Satellite Meeting: Queenstown Research Week, Queenstown, New Zealand.

2021

Journal - Research Article

Chand, R. R., Nimick, M., Cridge, B., & Rosengren, R. J. (2021). In vitro hepatic assessment of cineole and Its derivatives in common brushtail possums (Trichosurus vulpecula) and rodents. Biology, 10, 1326. doi: 10.3390/biology10121326

Conference Contribution - Published proceedings: Abstract

Chand, R. R., Nimick, M., & Rosengren, R. (2021). In vitro hepatic assessment of cineole and its derivatives in common brushtail possums and rodents. In M. Colombo, P. Vakaoti, R. Richards, M. Schaaf, M. Taumoepeau & L. Moata'ane (Eds.), Proceedings of the Pacific Postgraduate Symposium: Pacific Voices XVIII. (pp. 9). Dunedin, New Zealand: Pacific Islands Centre, University of Otago. Retrieved from http://hdl.handle.net/10523/16236

2020

Journal - Research Article

Finlay, D. B., Sircombe, K. J., Nimick, M., Jones, C., & Glass, M. (2020). Terpenoids from cannabis do not mediate an entourage effect by acting at cannabinoid receptors. Frontiers in Pharmacology, 11, 359. doi: 10.3389/fphar.2020.00359

2019

Journal - Research Article

Shrestha, N., Nimick, M., Dass, P., Rosengren, R. J., & Ashton, J. C. (2019). Mechanisms of suppression of cell growth by dual inhibition of ALK and MEK in ALK-positive non-small cell lung cancer. Scientific Reports, 9, 18842. doi: 10.1038/s41598-019-55376-4

Bland, A. R., Bower, R. L., Nimick, M., Hawkins, B. C., Rosengren, R. J., & Ashton, J. C. (2019). Cytotoxicity of curcumin derivatives in ALK positive non-small cell lung cancer. European Journal of Pharmacology, 865, 172749. doi: 10.1016/j.ejphar.2019.172749

Shrestha, N., Lateef, Z., Martey, O., Bland, A. R., Nimick, M., Rosengren, R., & Ashton, J. C. (2019). Does the mouse tail vein injection method provide a good model of lung cancer? F1000Research, 8, 190. doi: 10.12688/f1000research.17964.1

Conference Contribution - Poster Presentation (not in published proceedings)

Shrestha, N., Bland, A. R., Bower, R. L., Nimick, M., Rosengren, R. J., & Ashton, J. C. (2019, September). Toxicity and efficacy of crizotinib and selumetinib combination therapy in in vivo xenograft model of ALK-positive lung cancer. Poster session presented at the Medical Sciences Congress (MedSci), Queenstown, New Zealand.

2018

Journal - Research Article

Chen, S., Nimick, M., Cridge, A. G., Hawkins, B. C., & Rosengren, R. J. (2018). Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer. International Journal of Oncology, 52(2), 579-588. doi: 10.3892/ijo.2017.4207

Conference Contribution - Published proceedings: Abstract

Shrestha, N., Nimick, M., Rosengren, R., & Ashton, J. (2018). Synergistic cytotoxicity through MAPK/ERK pathway and ALK inhibition in crizotinib resistant EML4-ALK-positive lung cancer. Journal of Thoracic Oncology, 13(10, Suppl.), (pp. S699). doi: 10.1016/j.jtho.2018.08.1143

Bland, A., Nimick, M., & Ashton, J. (2018). Metformin in combination with crizotinib for the treatment of EML4-ALK+ lung cancer. Journal of Thoracic Oncology, 13(Suppl. 10), (pp. S460-S461). doi: 10.1016/j.jtho.2018.08.561

Conference Contribution - Poster Presentation (not in published proceedings)

Bower, R. L., Nimick, M., Shrestha, N., Bland, A., Rosengren, R., & Ashton, J. C. (2018, August). Toward a cell-based model of metastatic prostate cancer: Isolation and characterisation of metastatic prostate cancer cells derived from an orthotopically implanted SCID mouse model. Poster session presented at the Medical Sciences Congress (MedSci), Queenstown, New Zealand.

Conference Contribution - Verbal presentation and other Conference outputs

Shrestha, N., Nimick, M., Rosengren, R. J., & Ashton, J. C. (2018, August). MAPK/ERK pathway and ALK inhibition has synergistic cytotoxicity in crizotinib resistant EML4-ALK-positive lung cancer. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2017

Journal - Research Article

Wilson, C., Nimick, M., Nehoff, H., & Ashton, J. C. (2017). ALK and IGF-1R as independent targets in crizotinib resistant lung cancer. Scientific Reports, 7, 13955. doi: 10.1038/s41598-017-14289-w

Martey, O., Nimick, M., Taurin, S., Sundararajan, V., Greish, K., & Rosengren, R. J. (2017). Styrene maleic acid-encapsulated RL71 micelles suppress tumor growth in a murine xenograft model of triple negative breast cancer. International Journal of Nanomedicine, 12, 7225-7237. doi: 10.2147/ijn.s148908

Conference Contribution - Published proceedings: Abstract

Chen, S., Nimick, M., & Rosengren, R. J. (2017). Anticancer potential of novel curcumin analogues towards hormone-refractory prostate cancer. Proceedings of theSociety of Toxicology (SOT) Annual Meeting. (pp. 63-64). Retrieved from http://www.toxicology.org

Martey, O. N., Nimick, M., Taurin, S., Greish, K., & Rosengren, R. J. (2017). A novel role for SMA-RL71 naomicelles in the suppression of tumor growth in a triple negative breast cancer xenograft model. The Toxicologist. (pp. 16-17). [Abstract]

Conference Contribution - Verbal presentation and other Conference outputs

Wilson, C., Shrestha, N., Nimick, M., Nehoff, H., & Ashton, J. C. (2017, September). Drug combinations for ALK+ lung cancer. Verbal presentation at the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists New Zealand Section (ASCEPT-NZ) Annual Scientific Meeting, Queenstown, New Zealand.

2016

Journal - Research Article

Taurin, S., Nimick, M., Larsen, L., & Rosengren, R. J. (2016). A novel curcumin derivative increases the cytotoxicity of raloxifene in estrogen receptor-negative breast cancer cell lines. International Journal of Oncology, 48, 385-398. doi: 10.3892/ijo.2015.3252

Conference Contribution - Published proceedings: Abstract

Gwavava, P., Nimick, M., Taurin, S., Hawkins, B. C., & Rosengren, R. J. (2016). The curcumin derivative RL112 induces apoptosis in ovarian cancer cells. The Toxicologist. (pp. 75-76). [Abstract]

2014

Journal - Research Article

De Wever, V., Nasa, I., Chamousset, D., Lloyd, D., Nimick, M., Trinkle-Mulcahy, L., … Moorhead, G. B. G. (2014). The human mitotic kinesin KIF18A binds protein phosphatase 1 (PP1) through a highly conserved docking motif. Biochemical & Biophysical Research Communications, 453(3), 432-437. doi: 10.1016/j.bbrc.2014.09.105

Conference Contribution - Published proceedings: Abstract

Sundararajan, V., Taurin, S., Nimick, M., Jayawardena, N., Greish, K., & Rosengren, R. J. (2014). SMA-RL71 as a novel nanomedicine for triple negative breast cancer. Proceedings of the joint Drug Discovery & Therapy World Congress and the Global Biotchnology Congress. 61. Retrieved from http://www.ddtwc.com/

2013

Journal - Research Article

Skene-Arnold, T. D., Luu, H. A., Uhrig, R. G., De Wever, V., Nimick, M., Maynes, J., … Holmes, C. F. B. (2013). Molecular mechanisms underlying the interaction of protein phosphatase-1c with ASPP proteins. Biochemical Journal, 449(3), 649-659. doi: 10.1042/BJ20120506

2012

Journal - Research Article

Araújo, W. L., Tohge, T., Nunes-Nesi, A., Daloso, D. M., Nimick, M., Krahnert, I., … Fernie, A. R. (2012). Phosphonate analogs of 2-oxoglutarate perturb metabolism and gene expression in illuminated Arabidopsis leaves. Frontiers in Plant Science, 3, 114. doi: 10.3389/fpls.2012.00114

De Wever, V., Lloyd, D. C., Nasa, I., Nimick, M., Trinkle-Mulcahy, L., Gourlay, R., … Moorhead, G. B. G. (2012). Isolation of human mitotic protein phosphatase complexes: Identification of a complex between protein phosphatase 1 and the RNA helicase Ddx21. PLoS ONE, 7(6), e39510. doi: 10.1371/journal.pone.0039510

Tran, H. T., Nimick, M., Uhrig, R. G., Templeton, G., Morrice, N., Gourlay, R., … Moorhead, G. B. G. (2012). Arabidopsis thaliana histone deacetylase 14 (HDA14) is an α-tubulin deacetylase that associates with PP2A and enriches in the microtubule fraction with the putative histone acetyltransferase ELP3. Plant Journal, 71(2), 263-272. doi: 10.1111/j.1365-313X.2012.04984.x

Journal - Research Other

Tran, H. T., Uhrig, R. G., Nimick, M., & Moorhead, G. B. (2012). Interfacing protein lysine acetylation and protein phosphorylation: Ancient modifications meet on ancient proteins [Short communication]. Plant Signaling & Behavior, (7), 8, 901-903. doi: 10.4161/psb.20704

Conference Contribution - Published proceedings: Abstract

Taurin, S., Nimick, M., & Rosengren, R. J. (2012). The combination of raloxifene and gefitinib is synergistically cytotoxic toward triple negative breast cancer cells. The Toxicologist. 126(1), (pp. 577). [Abstract]

Taurin, S., Yadav, B. D., Nimick, M., & Rosengren, R. J. (2012). A combination of raloxifene and gefitinib potentiates the cytotoxicity and induces apoptosis in estrogen receptor negative breast cancer cell lines. Proceedings of the American Association for Cancer Research (AACR) 103rd Annual Meeting. Retrieved from http://www.abstractsonline.com/plan/AdvancedSearch.aspx

2011

Conference Contribution - Published proceedings: Abstract

Tran, K., Nimick, M., Taurin, S., Yadav, B., & Rosengren, R. J. (2011). WIN55,212-2 as a potential treatment for estrogen-receptor negative breast cancer. European Journal of Cancer, 47(Suppl. 1), (pp. S155-S156). [Abstract]